Patients With HIV Prefer Long-Acting Cabotegravir Plus Rilpivirine Injection Over Daily Oral ART, Study Finds

Infectious Disease Advisor (7/2, Nye) reports, “Long-acting injections of cabotegravir (CAB) plus rilpivirine (RPV) were found to be tolerable over the long term among patients with HIV infection, according to findings published in Open Forum Infectious Diseases.” In the study, “when asked about ideal therapy for HIV management, many patients indicate a preference for a less frequent dosing schedule. Long-acting CAB plus RPV injections present a viable option for addressing this preference as the recommended frequency of administration is once monthly or once every 2 months.”